Korcáková L, Kolc J, Málek P, Svobodová J
Transplantation. 1980;29(1):51-3. doi: 10.1097/00007890-198001000-00011.
Human lymphocytes treated in vitro with Mercurascan (MSC) have a reduced capacity to form E rosettes and to respond to phytohemagglutinin. MSC was also found to reduce the capacity of mouse lymphocytes to activate the regional lymph nodes of allogeneic recipients and release the lymph node-activating factor.
体外经美拉司康(MSC)处理的人淋巴细胞形成E花环以及对植物血凝素作出反应的能力降低。还发现MSC会降低小鼠淋巴细胞激活同种异体受体局部淋巴结并释放淋巴结激活因子的能力。